Beyond Traditional Methods: New Approaches to Help Those Who Smoke

Cigarette smoking remains the leading cause of preventable disease and death in the United States, killing more than 480,000 Americans each year and costing the nation over $600 billion annually in healthcare expenditures and lost productivity. Despite these well-documented harms, the overwhelming majority of people who smoke and try to quit are unsuccessful. In 2022, approximately 53 percent of adult smokers in the United States reported making a quit attempt, yet fewer than 9 percent succeeded. When combined with behavioral counseling, currently approved treatments like nicotine replacement therapy (NRT), varenicline, and bupropion produce long-term success rates of only about 20 to 30 percent under ideal conditions. Given that two-thirds of current smokers want to quit, these modest outcomes represent an enormous unmet medical need and a demand for innovative alternatives. Emerging research is examining whether psilocybin, the psychoactive compound in “magic mushrooms,” could be one such innovation. 

A Potential Psychedelic Breakthrough

Researchers at Johns Hopkins University recently conducted a pilot randomized clinical trial to test the promise of psilocybin as a tool to help smokers quit. One group received a single high dose of psilocybin, while the other was given a standard course of nicotine patches. Both groups also received 13 weeks of cognitive behavioral therapy. The results were intriguing: At six months, 40.5 percent of participants in the psilocybin group demonstrated biochemically verified prolonged smoking abstinence compared to just 10 percent in the nicotine patch group.

Unlike conventional cessation drugs, psilocybin does not target nicotinic receptors. Instead, it binds to and activates serotonin 2A receptors, likely promoting cessation by prompting shifts in self-concept and breaking entrenched cognitive patterns. However, the study had important limitations: a small sample (82 participants), limited demographic diversity, an un-blinded design, and comparison against the nicotine patch alone rather than more efficacious treatments. The National Institutes of Health has funded a larger, placebo-controlled follow-up trial, signaling that the scientific community considers these preliminary findings worthy of rigorous validation. 

Other Emerging Treatments

Several other innovative approaches are advancing through clinical trials. 

• Cytisinicline is a plant-derived partial agonist of nicotinic receptors used in Eastern Europe for decades. It showed strong results in the ORCA-2 trial, where a 12-week course produced continuous abstinence rates of 32.6 percent versus 7 percent for placebo. 
• Transcranial magnetic stimulation (TMS) is a non-pharmacological brain stimulation technique. It earned 510(k) clearance for short-term smoking cessation from the U.S. Food and Drug Administration in 2020 (the first TMS indication for any addiction) after a pivotal trial demonstrated four-week quit rates of 28 percent versus 11.7 percent for sham treatment. 
• Digital therapeutics combine virtual reality with mobile app-based therapy. They have facilitated significant reductions in smoking in pilot studies, offering promise for scalable, low-cost interventions.  
• GLP-1 receptor agonists like semaglutide, primarily used for diabetes and obesity, appear to modulate central reward pathways involved in nicotine addiction. Early evidence suggests they may reduce nicotine cravings while also mitigating the weight gain that often accompanies quitting—a significant barrier for many who smoke.  

Reduced Risk Products: Quitting Smoking, Not Quitting Nicotine

A critical distinction sometimes lost in public health discourse is the difference between quitting smoking and quitting nicotine. The overwhelming burden of tobacco-related disease stems not from nicotine itself but from the combustion of tobacco, which releases thousands of toxic and carcinogenic compounds. This understanding has driven interest in reduced-risk products like e-cigarettes, heated tobacco products, and oral nicotine products like snus and nicotine pouches as tools to help those who smoke transition away from combustible cigarettes.

The most recent Cochrane systematic review found high-certainty evidence that nicotine e-cigarettes increase quit rates compared to NRT, translating to approximately three additional quitters per 100 smokers. Perhaps the most compelling population-level evidence comes from Sweden, which in October 2025 became the first country in Europe to achieve “smoke-free” status. Daily smoking rates have fallen below 5 percent, driven in significant part by pragmatic policies making lower-risk nicotine alternatives accessible and affordable. Sweden now has the lowest smoking-related mortality rate in the European Union. 

Reduced-risk products are not without controversy, and concerns about youth uptake and dual use warrant ongoing monitoring. Nevertheless, for those who smoke and have tried and failed to quit using approved pharmacotherapies, these products may represent a pragmatic, evidence-informed pathway away from the most harmful form of nicotine delivery.

A Broader Vision for Cessation

With nearly half a million Americans dying from tobacco use each year and traditional cessation methods succeeding for fewer than one in 10 unaided quit attempts, there is an urgent need for innovative solutions. The research reviewed here demonstrates that the cessation landscape is expanding in promising directions, from psilocybin-assisted therapy and new medications to brain stimulation, digital tools, and reduced-risk products backed by high-certainty evidence and real-world success. The principle that should guide clinicians, policymakers, and public health advocates is one of compassion and pragmatism: Every person who smokes and wants to quit deserves access to the full spectrum of evidence-based options. The ultimate measure of success is not ideological purity, but the reduction of suffering and premature death.